Thread by @RiyaSam12

#AHA22 LBCTs one liners:

1. TRANSFORM-HF: Torsemide was not superior to furosemide in improving survival among patients treated for decompensated HF.

2. DCP: No differences in cardiovascular outcomes between chlorthalidone and HCTZ among elderly veterans with HTN.

3. PROMINENT: Pemafibrate did not improve cardiovascular outcomes among patients with diabetes and hypertriglyceridemia.

4. IRONMAN: Iron (ferric derisomaltose) infusion is not superior to usual care among patients with HF and iron deficiency.

5. EMPA KIDNEY: Empagliflozin has salutary effects on renal function and CV mortality among patients with CKD, with or without DM, who are already on appropriate doses of ACEi/ARB.

6. RESPECT-EPA: Highly purified eicosapentaenoic acid showed borderline statistical sig in reducing the risk of adverse CV events in Japanese w/ c/c CAD who were being treated w/ statins.

7. OCEAN(a) DOSE: Olpasiran significantly reduced lipoprotein(a) in established ASCVD.

8. SPORT: Rosuvastatin 5 mg daily lowered LDL-C significantly >placebo, fish oil, cinnamon, garlic, turmeric, plant sterols in those with increased 10-year risk for ASCVD.

9. RAPCO-RITA: Radial artery bypass graft improves adverse CV outcomes vs R internal thoracic artery BG

10. RAPCO-SV: Radial artery bypass graft improves adverse CV outcomes VS a saphenous vein BG.

11. CRHCP: village doctor-led HTN intervention was effective in reducing cardiovascular disease and all-cause mortality in rural villages in China compared with usual care.

12. QUARTET USA:4 drug, quarter-dose BP-lowering combination of candesartan, amlodipine, indapamide and bisoprolol led to a greater reduction in change in BP from baseline to 12 weeks compared with standard-dose ARB monotherapy in patients with mild to moderate HTN.

13. MB-BP: adults w/ HTN who participated in a mindfulness behavior program for 8 wks had significantly lower BP levels & greatly reduced sedentary time, at 6 months follow-up VS those who received enhanced usual care (home BP monitor/BP edu/facilitated access to a physician)

14. CTS-AMI: Tongxinluo (TXL), a traditional Chinese medicine approved to treat angina and stroke in China, significantly improved both the 30 day and 1 year clinical outcomes of Chinese patients with STEMI.

15. COACH: systematic use of a hospital-based POC tool to support clinical decision-making, followed by rapid follow-up in an outpatient clinic, led to a lower risk of death or hospitalization for CV causes within 30 days among patients with acute HF seeking emergency care.

16. CRISPR: a single IV infusion of NTLA-2001, a novel gene-editing therapy based on CRISPR/Cas9, significantly reduced abnormal levels of the TTR protein by > 90% in patients with ATTR amyloid CM after 28 days.

17. PRO-HF: Routine collection of patient-reported health status using KCCQ-12 in the HF clinic improved accuracy of clinician assessments of patients' health status.

18. STRESS: Prophylactic methylprednisolone in infants undergoing cardiopulmonary bypass heart surgery did not improve post-operative outcomes compared with placebo.

19. BRIGHT-4: Bivalirudin w/ a median 3hr post-PCI high-dose infusion significantly reduced the 30d composite rate of all-cause mortality/BARC types 3-5 major bleeding compared with heparin monotherapy in Chinese patients with STEMI undergoing primary PCI w/ radial artery access.

20. OPTION: DAPT with indobufen plus clopidogrel significantly reduced the risk of 1 year net clinical outcomes in Chinese patients with negative cardiac troponin undergoing DES implantation, compared to conventional DAPT of aspirin plus clopidogrel.

21. PRECISE: A personalized "precision" testing approach led to more efficient evaluations for cardiovascular disease risk and improved diagnosis and treatment of CAD when compared to usual care in more than 2,000 adults with stable chest pain.

22. PREVENT-HD: Early initiation of rivaroxaban, prescribed for 35 days in non-hospitalized patients with symptomatic COVID-19 at-risk for thrombosis, was not found to reduce a composite endpoint of venous and arterial thrombotic events, hospitalization, and death.

23. IMPROVE: A universal EHR integrated CDS tool using a validated VTE risk model significantly increased rates of in-hospital appropriate thromboprophylaxis & significantly reduced major thromboembolic events w/o an increase in major bleeding at 30d post-discharge VS usual care

24. PROGRESSIVE - AF: First-line catheter ablation was associated with a significantly lower progression to persistent Afib, when compared to initial antiarrhythmic drug therapy.

25. NOVA: No significant differences in the rate of postoperative Afib in cardiac surgery patients who received either 125U or 250U doses of botulinum toxin type A (AGN-151607) compared with placebo.

26. ENHANCE - AF: implementation of a novel shared decision-making toolkit designed for low health literacy achieved significantly lower decisional conflict and improved preparation for decision-making compared to usual care in patients with AFib.

27. PRECISION: Among patients with resistant HTN, Aprocitentan resulted in short-term and sustained BP-lowering effects.

28. BrigHTN: Among patients with treatment-resistant HTN aldosterone synthase inhibition with Baxdrostat led to dose-dependent reductions in SBP.

29. BEST CLI: In those w/ CLTI surgical revascularization w/ a great saphenous venous conduit was superior to endovascular intervention in reducing major adverse limb events or death.

30. BEST-CLI QOL: Greater QOL improv in those undergoing endovascular intervention VS surgery.

32. RAPID: Etripamil nasal spray was effective in termination of spontaneous PSVT in patients experiencing an episode in an at-home setting.

33. EARLY AF: Catheter ablation reduces the incidence of persistent AFib/recurrent atrial tachyarrhythmia vs antiarrhythmic therapy.

34. STRONG HF: An intensive treatment strategy of rapid up-titration of GDMT and close follow-up after an acute HF admission reduced symptoms, improved QOL and reduced the risk of 180-day all-cause death or HF readmission compared with usual care.

35. ISCHEMIA EXTENDED: Among patients with stable ischemic heart disease and moderate to severe ischemia on noninvasive stress testing, routine invasive therapy failed to reduce major adverse cardiac events compared with optimal medical therapy.

@ACCinTouch @IllinoisACC @AbhiKulk82 @HeartOTXHeartMD @DrMarthaGulati @PamelaBMorris @NMHheartdoc @ErinMichos @ditchhaporia @HFnursemaghee @melsulistio @MelvinEchols9 @AHAScience @CMichaelGibson